NasdaqCM - Delayed Quote • USD
Lipocine Inc. (LPCN)
At close: April 22 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.68 | -0.62 | -1.49 | -0.57 |
| Low Estimate | -0.68 | -0.62 | -1.49 | -0.57 |
| High Estimate | -0.68 | -0.62 | -1.49 | -0.57 |
| Year Ago EPS | -0.68 | -0.68 | -3.14 | -1.49 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | 400k | 2.03M | 16.25M |
| Low Estimate | -- | 400k | 2.03M | 16.25M |
| High Estimate | -- | 400k | 2.03M | 16.25M |
| Year Ago Sales | 55k | -- | -2.85M | 2.03M |
| Sales Growth (year/est) | -- | -- | -171.20% | 700.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.42 | -0.64 | -0.6 | -0.47 |
| EPS Actual | -0.68 | -0.68 | -1.27 | -0.42 |
| Difference | -0.26 | -0.04 | -0.67 | 0.05 |
| Surprise % | -61.90% | -6.30% | -111.70% | 10.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.68 | -0.62 | -1.49 | -0.57 |
| 7 Days Ago | -0.68 | -0.62 | -1.49 | -0.57 |
| 30 Days Ago | -0.68 | -0.62 | -1.49 | -0.57 |
| 60 Days Ago | -0.35 | -0.32 | -1.21 | -0.57 |
| 90 Days Ago | -0.35 | -0.32 | -1.21 | -0.57 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LPCN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 0.20% |
| Next Qtr. | 8.80% | -- | -- | 9.40% |
| Current Year | 52.50% | -- | -- | 4.40% |
| Next Year | 61.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 7/27/2023 |
Related Tickers
TRVN Trevena, Inc.
0.3702
+5.17%
ATHE Alterity Therapeutics Limited
2.1300
+3.40%
NRXP NRx Pharmaceuticals, Inc.
3.0000
-1.32%
CDTX Cidara Therapeutics, Inc.
0.5139
-24.54%
VINC Vincerx Pharma, Inc.
0.8690
+2.24%
ASLN ASLAN Pharmaceuticals Limited
0.4550
-11.13%
CNTB Connect Biopharma Holdings Limited
1.3500
-10.00%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0900
+2.32%
TCON TRACON Pharmaceuticals, Inc.
1.8200
-7.14%
MIST Milestone Pharmaceuticals Inc.
1.6300
-0.61%